Sinovac Biotech Ltd

Sinovac Biotech Ltd. is a biopharmaceutical company focused on the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. Its product portfolio includes vaccines for hepatitis A and B, hand, foot, and mouth disease caused by enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, varicella, and mumps. Marketed products include Healive, Bilive, Anflu, Panflu, Panflu.1, a mumps vaccine, a split viron pandemic influenza vaccine, Inlive, a varicella vaccine, a pneumococcal polysaccharide vaccine, a quadrivalent influenza vaccine, and CoronaVac. The company has collaboration agreements with GlaxoSmithKline Biologicals SA, Tianjin CanSino Biotechnology Inc., and Instituto Butantan. Founded in 1993, Sinovac Biotech Ltd. is headquartered in Beijing, the People's Republic of China.